Investors Menu

Press Releases

« Back to news

LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

January 4, 2022 at 8:00 AM EST

LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the virtual H.C. Wainwright Bioconnect Conference being held January 10-13, 2022. The pre-recorded presentation will be available for on-demand viewing beginning at 7:00 a.m. ET on Monday, January 10, 2022.

A webcast of the presentation will be made available on the Investors section of the Company's website at The webcast replay will be available for approximately 30 days.

About LogicBio Therapeutics 

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit, which does not form a part of this release.

Investor Contacts:   
Stephen Jasper 
Gilmartin Group 

Media Contacts: 
Adam Daley 
Berry & Company Public Relations 
C: 614-580-2048

Cision View original content:

SOURCE LogicBio Therapeutics, Inc.